Regeneron Pharmaceuticals Inc REGN delivered mixed results for the third quarter. While earnings beat estimates, revenue fell shy of the expectations.
The company boosted the lower end of its full year EYLEA net product sales forecast in the United States.
- Reports adjusted EPS of $3.13, beats by $0.42.
- Delivers revenue of $1.22 billion, misses by $0.07 billion.
- Lifted the EYLEA net product sales growth in the United States from 20–25 percent to 23–25 percent from the previous year period.
Regeneron’s president and CEO, Leonard Schleifer, commented, "In the third quarter, we saw continued U.S. sales growth with EYLEA in retinal diseases and with Praluent in hypercholesterolemia. We are preparing for a potential approval and launch for Dupixent in atopic dermatitis and continuing to advance our pipeline at all stages."
The stock closed at $336.01 on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
